Author: Aarya Shah | EQMint | Market News
In a major win for domestic pharmaceutical innovation and access to rare disease treatments, Natco Pharma’s shares jumped nearly 6% after the Delhi High Court allowed the company to sell ‘Risdiplam’, a crucial drug used for treating spinal muscular atrophy (SMA), in India. The court ruling marks a pivotal moment for both patients battling the rare genetic disorder and the Indian pharmaceutical landscape, which has long sought greater autonomy in life-saving drug production.
Court’s Decision and Background
The Delhi High Court, in its recent verdict, dismissed a plea by Swiss drugmaker Roche, which had sought to restrain Natco Pharma from manufacturing and selling the SMA drug under its own brand name. Roche holds the patent for Risdiplam, marketed globally as Evrysdi. However, the court observed that Natco’s version did not infringe upon the existing patent and allowed the company to continue its domestic production and distribution.
This legal outcome is expected to significantly improve access to SMA treatment in India, where the imported version of the drug costs an astronomical sum, often running into lakhs per month — an expense unaffordable for most families.
Justice C Hari Shankar, who presided over the case, reportedly held that the “patent rights must balance innovation with public accessibility,” highlighting the need to make life-saving drugs more affordable in developing nations like India.
What is Risdiplam and Why It Matters
Risdiplam is an oral medication prescribed for Spinal Muscular Atrophy (SMA), a rare neuromuscular disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and loss of movement. The condition, often diagnosed in infants and young children, can be life-threatening without early and consistent treatment.
Before Natco’s entry, patients in India depended on imported versions supplied by Roche and a handful of authorized distributors, at costs that severely limited availability. With Natco Pharma’s local version cleared for sale, treatment costs could reduce by up to 80%, according to early market estimates.
Boost for Affordable Healthcare
This ruling is not just a corporate victory but a landmark for India’s healthcare affordability mission. The Indian government and healthcare activists have long advocated for the production of generic and affordable versions of expensive patented drugs — particularly for rare diseases that require long-term, high-cost medication.
Natco Pharma’s move aligns with this vision, as the company has been at the forefront of introducing cost-effective treatments in oncology, cardiology, and now, rare genetic conditions.
“This is a win for patients as much as it is for the company,” said a senior healthcare analyst. “By entering the SMA treatment space, Natco is ensuring that thousands of families no longer have to choose between financial ruin and saving their loved ones.”
Market Reaction
Following the court order, Natco Pharma’s stock surged over 6% in intraday trading, touching a new 52-week high on the NSE. Investors viewed the ruling as a major growth catalyst, especially given the potential size of the rare disease market in India and the limited competition in this niche segment.
Market experts believe the approval could contribute significantly to Natco’s revenue growth over the next few quarters. “This legal clearance allows Natco to tap into a high-value, low-competition therapeutic area,” said an equity analyst. “The SMA market, though small in patient count, has high revenue potential due to chronic treatment requirements.”
Broader Implications for the Pharma Sector
The verdict could have far-reaching implications for India’s pharmaceutical ecosystem. It reinforces the judiciary’s balanced approach between protecting intellectual property and ensuring affordable access to essential medicines — a principle enshrined in India’s patent laws.
The case also underscores the growing capability of Indian drugmakers to innovate and develop complex molecules previously dominated by global pharma giants. Natco Pharma, known for its generic versions of high-end cancer drugs like Sorafenib and Lenalidomide, continues to push boundaries in research and legal strategy.
What’s Next for Natco Pharma
Industry insiders suggest that Natco may soon roll out its version of Risdiplam under a distinct brand name, with distribution expected to start within the next few months. The company is likely to collaborate with government health programs and hospitals to ensure broad patient outreach.
Furthermore, this success could encourage other Indian companies to enter the rare disease drug space — a field that has remained underdeveloped due to patent restrictions and high R&D costs.
A Step Toward Self-Reliance
The court’s ruling dovetails with India’s broader Atmanirbhar Bharat (self-reliant India) vision, which aims to strengthen domestic production in critical health sectors. By enabling Indian companies to legally produce and market vital drugs, the country is taking another step toward healthcare independence.
In a landscape often dominated by global pharmaceutical monopolies, Natco Pharma’s victory reaffirms India’s role as a champion of affordable medicine and equitable healthcare.
As the stock market celebrates this legal win, the greater triumph lies in the hope it offers to countless families who can now access a once out-of-reach treatment — turning a corporate milestone into a humanitarian breakthrough.
Disclaimer: This article is based on information available from public sources. It has not been reported by EQMint journalists. EQMint has compiled and presented the content for informational purposes only and does not guarantee its accuracy or completeness. Readers are advised to verify details independently before relying on them.
